Pitt Street Research | Stock research
Percheron Therapeutics.png

Percheron Therapeutics

Percheron Therapeutics is an Australian drug developer whose lead compound is HMBD-002, a potential immuno-oncology drug. HMBD-002 is a monoclonal antibody that targets an immune checkpoint called VISTA. The drug has shown promise in a recently completed a Phase 1 study in multiple tumour types, in terms of both its safety and potential efficacy. Percheron in-licensed the drug in June 2025.

Percheron Therapeutics (ASX:PER)

 

Percheron Therapeutics is an Australian drug developer whose lead compound is HMBD-002, a potential immuno-oncology drug. HMBD-002 is a monoclonal antibody that targets an immune checkpoint called VISTA. The drug has shown promise in a recently completed a Phase 1 study in multiple tumour types, in terms of both its safety and potential efficacy. Percheron in-licensed the drug in June 2025.